(PhRMA) president and CEO Stephen J. Ubl issued the following statement on President Donald Trump’s drug pricing blueprint: “These far-reaching proposals could fundamentally change how patients access medicines and realign incentives across the entire prescription drug supply chain. While some of these proposals could help make medicines more affordable for patients, others would disrupt coverage and limit patients’ access to innovative treatments”. Folks, that is chutzpah.
Trump’s proposal on controlling drug prices is a farce, long on slogans, short on anything that will lower drug prices. But then again, let’s look at who is making these drug policies:
Alex Azar: Secretary of Health was the former head of Lilly’s US division, which has consistently raised insulin prices.
Scott Gottlieb: FDA Commissioner, Received more than $400,000 from big pharma between 2013-2015.
Daniel Best, who wrote the plan to lower Rx drug prices, former Director of Business Development for Pfizer.
Joe Grogran who wrote Trump’s health budget, was a lobbyist for Gilead.
Keep in mind that this comes at a time when:
So on top of all this PhRMA is saying that Trump’s plan is unfair?! P L E A S E.
This is a huge load of ammunition for the next election(s) and you can bet that pharma pricing is going to be right in the central target area. So far the only pharma company who foresees that a storm is coming is GSK. The others are just continuing to do business the same way as before.
There are none so stupid as those who refuse to acknowledge change.